Prosecution Insights
Prosecution Insights
17 pending office actions • 14 art units • 17 examiners • 0 of 17 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (12%) |
| §103 only | 3 (18%) |
| §102 only | 1 (6%) |
| Double-patenting only | 1 (6%) |
| Double-patenting + other | 5 (29%) |
| Multi-statute (no §101) | 5 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAMSELL, RILLA MARIE | 1 | 72.0% | +15.0% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.5% |
| HA, JULIE | 1 | 75.6% | +44.2% |
| KIM, DANIELLE A | 1 | 36.7% | +57.5% |
| CLARK, AMY LYNN | 1 | 39.1% | +30.9% |
| XU, XIAOYUN | 1 | 59.9% | +31.9% |
| HERNANDEZ, JACKSON J | 1 | 50.9% | +28.8% |
| HILL, GRACELYN MARKHAM | 1 | 100.0% | +0.0% |
| SALMON, KATHERINE D | 1 | 42.6% | +38.0% |
| STEELE, AMBER D | 1 | 59.0% | +9.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17827584 | COMPOSITIONS AND METHODS FOR TREATING NERVOUS SYSTEM INJURIES | BRADLEY, CHRISTINA | 103d overdue |
| 18415255 | USES OF HNF4 ALPHA AGONISTS | CLARK, AMY LYNN | 62d |
| 18710429 | INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF | WILLIS, DOUGLAS M | — |
| 18273686 | SARS-COV-2 THERAPEUTICS | HERNANDEZ, JACKSON J | — |
| 18327715 | MICROSCOPIC IMAGING AND ANALYSES OF EPIGENETIC LANDSCAPE | HILL, GRACELYN MARKHAM | — |
| 18251045 | PROGNOSTIC BIOMARKERS FOR BREAST CANCER | SALMON, KATHERINE D | — |
| 18172116 | COMPOSITIONS AND METHODS FOR TREATING DISEASES | STEELE, AMBER D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18419387 | TYRAMINE CONTAINING HYDROXYCINNAMIC ACID AMIDE DERIVATIVES AND METHODS OF USE THEREOF | KIM, DANIELLE A | 50d overdue |
| 18361439 | METHODS AND COMPOSITIONS FOR DETECTING COGNITIVE DISORDER | XU, XIAOYUN | 35d overdue |
| 18652429 | TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF | HA, JULIE | 14d |
| 18415255 | USES OF HNF4 ALPHA AGONISTS | CLARK, AMY LYNN | 62d |
| 18775510 | USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION | SAMSELL, RILLA MARIE | — |
| 18710429 | INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF | WILLIS, DOUGLAS M | — |
| 18273686 | SARS-COV-2 THERAPEUTICS | HERNANDEZ, JACKSON J | — |
| 18251045 | PROGNOSTIC BIOMARKERS FOR BREAST CANCER | SALMON, KATHERINE D | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1613 | 1 |
| 1628 | 1 |
| 1797 | 1 |
| 1627 | 1 |
| 1656 | 1 |
| 1682 | 1 |
| 1658 | 1 |
| 1651 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18775510 | USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION | SAMSELL, RILLA MARIE | — | §102§103§112DPOther | Non-Final OA | — | Pending | Jul 17, 2024 |
| 18710429 | INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF | WILLIS, DOUGLAS M | — | §102§112 | Non-Final OA | — | Pending | May 15, 2024 |
| 18652429 | TUMOR ASSOCIATED MONOCYTE/MACROPHAGE BINDING PEPTIDE AND METHODS OF USE THEREOF | HA, JULIE | 1654 | DP | Final Rejection | 14d | Pending | May 01, 2024 |
| 18419387 | TYRAMINE CONTAINING HYDROXYCINNAMIC ACID AMIDE DERIVATIVES AND METHODS OF USE THEREOF | KIM, DANIELLE A | 1613 | §103DP | Final Rejection | 50d overdue | Pending | Jan 22, 2024 |
| 18415255 | USES OF HNF4 ALPHA AGONISTS | CLARK, AMY LYNN | 1628 | §102§103 | Non-Final OA | 62d | Pending | Jan 17, 2024 |
| 18361439 | METHODS AND COMPOSITIONS FOR DETECTING COGNITIVE DISORDER | XU, XIAOYUN | 1797 | §103 | Final Rejection | 35d overdue | Pending | Jul 28, 2023 |
| 18273686 | SARS-COV-2 THERAPEUTICS | HERNANDEZ, JACKSON J | 1627 | §103§112 | Non-Final OA | — | Pending | Jul 21, 2023 |
| 18327715 | MICROSCOPIC IMAGING AND ANALYSES OF EPIGENETIC LANDSCAPE | HILL, GRACELYN MARKHAM | 1656 | §101§102§112 | Non-Final OA | — | Pending | Jun 01, 2023 |
| 18251045 | PROGNOSTIC BIOMARKERS FOR BREAST CANCER | SALMON, KATHERINE D | 1682 | §103§112 | Final Rejection | — | Pending | Apr 28, 2023 |
| 18172116 | COMPOSITIONS AND METHODS FOR TREATING DISEASES | STEELE, AMBER D | 1658 | §103§112Other | Non-Final OA | — | Pending | Feb 21, 2023 |
| 17906818 | COMPOSITIONS AND METHODS FOR TREATING SERRATED COLORECTAL CANCER | CLARKE, TRENT R | 1651 | §103Other | Non-Final OA | 42d overdue | Pending | Sep 20, 2022 |
| 17799641 | MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS | LEE, WILLIAM Y | 1623 | §112DP | Final Rejection | 145d overdue | Pending | Aug 12, 2022 |
| 17799639 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | MCDOWELL, BRIAN E | 1624 | §102 | Non-Final OA | 29d | Pending | Aug 12, 2022 |
| 17812126 | METHODS FOR REVERSING HEPATIC STEATOSIS | WELLS, LAUREN QUINLAN | 1622 | §103§112DP | Final Rejection | — | Pending | Jul 12, 2022 |
| 17828627 | METHOD FOR IMPROVING DIGESTIVE HEALTH | MELLER, MICHAEL V | 1655 | §102§103DP | Non-Final OA | 67d overdue | Pending | May 31, 2022 |
| 17827584 | COMPOSITIONS AND METHODS FOR TREATING NERVOUS SYSTEM INJURIES | BRADLEY, CHRISTINA | 1654 | §101§102§112Other | Final Rejection | 103d overdue | Pending | May 27, 2022 |
| 17773775 | METABOLIC REPROGRAMMING OF IMMUNE CELLS TO ENHANCE THE EFFICACY OF PROPHYLACTIC AND THERAPEUTIC VACCINES | RICCI, CRAIG D | 1611 | §103 | Final Rejection | 97d overdue | Pending | May 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial